Bone marrow predominant presentation of EGFR mutated NSCLC: Report of two cases. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42433726
Explore two unique cases of EGFR-mutated NSCLC with predominant bone marrow involvement, a rare initial finding. Treatment success matched usual EGFR-positiv...
Two cases of EGFR-mutated NSCLC presented with predominant bone marrow involvement, confirmed by biopsy. Treatment outcomes were comparable to typical presentations. Disease Condition: NSCLC. Specialty Focus: Oncology.
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42395618
Discover how bsAbs like amivantamab tackle solid tumors, offering benefits while addressing challenges like antigen heterogeneity and immunosuppressive microenvironment.
BsAbs like amivantamab and tebentafusp show durable benefits in solid tumors, but face challenges like antigen heterogeneity and immunosuppressive microenvironment.
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41442468
The Italian ATLAS registry highlights the real-world safety of adjuvant atezolizumab in NSCLC patients with PD-L1 ≥50%, EGFR/ALK wild type, stages IIA-IIIB. Explore its clinic...
Adjuvant atezolizumab shows comparable safety to IMPower-010 in NSCLC patients with PD-L1 ≥50%, EGFR/ALK wild type, stages IIA-IIIB. Italian ATLAS registry offers valuable real-world evidence.
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41934464
Explore early radiotherapy for EGFR-mutant oligometastatic NSCLC, highlighting potential benefits from phase III trials and the need for further research on safety and strategies.
Early RT post-induction therapy in EGFR-mutant oligometastatic NSCLC shows potential benefits based on randomized phase III trials. Safety and optimal strategies require further research.
